Short answer
Foghorn Therapeutics Inc. (FHTX) filed an 8-K current report with the SEC on March 11, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure). Full-year 2025 financial results announced March 11, 2026: details in Exhibit 99.1 press release.
Foghorn Therapeutics Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Full-year 2025 financial results announced March 11, 2026: details in Exhibit 99.1 press release
- FHTX is a clinical-stage biotech; cash runway and R&D spend are key metrics to watch in the release
Item 7.01 · Regulation FD Disclosure
- Foghorn Therapeutics (FHTX) releasing updated investor presentation dated March 2026 for use in investor meetings
- Reg FD disclosure ensures all investors receive simultaneous access to material information shared in these meetings
- Full substance of disclosed information contained in Exhibit 99.2: review that exhibit for pipeline updates, data, or strategic messaging
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Foghorn Therapeutics Inc. 8-K filings
Get the next FHTX 8-K as it lands
Follow FHTX for push alerts, or ask the research agent what this filing means.